Magnolia Oil & Gas Corporation Class A Common Stock vs Pfizer Inc — how do they compare? Magnolia Oil & Gas Corporation Class A Common Stock trades at $24.9 (market cap $6.76B), while Pfizer Inc trades at $29.52 (market cap $161.70B). The key difference: Pfizer Inc is far larger — about 23.9× Magnolia Oil & Gas Corporation Class A Common Stock's market cap, and Pfizer Inc pays the higher dividend (6.06%). Which is the better fit depends on your goals — on Pluang, investors hold Magnolia Oil & Gas Corporation Class A Common Stock for 0 Days and Pfizer Inc for 158 Days on average.
| MGY | PFE | |
|---|---|---|
Market Cap | $6.76B | $161.70B |
Volume | 2,815,157 | 26,828,084 |
Sector | Energy | Health |
52-Week High | $32.36 | $29.21 |
52-Week Low | $21.24 | $23.67 |
Typical Hold Time | 0 Days | 158 Days |
Enterprise Value | $6.88B | $213.20B |
Dividend Yield | 2.63% | 6.06% |
Signals from Pluang's Aura AI — not financial advice
Magnolia Oil & Gas (MGY) trades at $25.11, up 2.66% with neutral technical signals. The company demonstrates strong fundamentals with a P/E of 10.97, net income margin of 28.77%, and consistent earnings beats. Recent WildFire Energy acquisition positions MGY for production doubling and significant free cash flow growth, with 2027 FCF projected over $1 billion. Analyst consensus remains strongly bullish with 66.7% buy ratings and $33.78 price target.
MGY presents compelling value with attractive valuation multiples and robust profitability metrics. The WildFire acquisition accelerates growth but introduces integration execution risk. Current price offers 35% upside to consensus target, though oil price volatility and operational execution remain key watchpoints for investors.
Pfizer (PFE) trades at $28.37, down slightly by 0.11% on the day, with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on obesity and oncology pipeline developments, positioning for a catalyst-rich 2026.
Pfizer presents a mixed outlook with stable revenue around $63B but declining net income projections for 2026. The stock trades near analyst consensus target of $29.17, offering modest upside potential. Key risks include patent cliffs and competitive pressures, while the dividend yield and pipeline progress provide defensive appeal for income-focused investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Magnolia Oil & Gas Corporation is an independent oil and gas exploration and production company operating in the Eagle Ford Shale and Austin Chalk formations of South Texas.
Read more on MGY →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →